Oncologie

Huidkanker

• AvelumabTreatment of adult patients with metastatic Merkel cell carcinoma (MCC) 
• BinimetinibTreatment of melanoma.  ^BS

• Ipilimumab

  • Ipilimumab ^IND
  • Ipilimumab ^BS
• MasitinibStaat 1x op excel  ^IND
• Nivolumab 
• PembrolizumabAdjuvant melanoma stage III.Keytruda · Malignant melanoma - post-resection adjuvant therapy in high-risk patients 

• Vemurafenib

  • Vemurafenib
  • Vemurafenib

Leukemie

• Blinatumomab

  • Blinatumomab
  • Blinatumomab
• CTL019Paediatric Acute Lymphatic Leukeamia (ALL): relapse and/or refractory patients, not eligible for SCT (3L?) 
• Gemtuzumab ozogamicin 
• Idelalisib  
• Inotuzumab ozogamicin 
• Midostaurin - in combination with standard daunorubicin and cytarabine induction and high dose cytarabine consolidation chemotherapy, and for patients in complete response followed by Rydapt single agent maintenance therapy, for adult patients with newly diagnosed acute myeloid leukaemia (AML) who are FLT3 mutation positive; - as monotherapy for the treatment of adult patients with aggressive systemic mastocytosis (ASM), systemic mastocytosis with associated haematological neoplasm (SM AHN), or mast cell leukaemia (MCL). 
• Venetoclax 

Borstkanker

• AbemaciclibBreast cancer, advanced, HR+ en HER2-, 1L or 2L. 

• Atezolizumab

  • Atezolizumab
  • Atezolizumab
• Etirinotecan pegol 
• Fulvestrant 
• Neratinib 
• OlaparibBreast cancer (HER2+, BCRA mutated; adjuv.) 
• Pertuzumab 

• Ribociclib

  • Ribociclib ^BS
  • Ribociclib

• Veliparib

  • Veliparib
  • Veliparib

Longkanker

• ABT-414Glioblastoma, 2L bij EGFR-amplificatie 
• AbemaciclibNSCLC advanced, KRAS-mutant, progression after platinum-based chemo 
• Alectinib 

• Atezolizumab

  • Atezolizumab ^BS
  • Atezolizumab
• AvelumabTreatment of locally advanced unresectable, metastatic or recurrent non-small cell lung cancer (NSCLC) after prior chemotherapy in adults, 2L. 
• Ceritinib 
• Dabrafenib + Trametinib 
• DurvalumabNon-small cell lung cancer (NSCLC) stage 4, PD-L1+, 1L 

• Nivolumab

  • Nivolumab
  • Nivolumab
  • Nivolumab
  • Nivolumab
• Nivolumab  
• Osimertinib 
• Pembrolizumab 
• Rociletinib 
• Rovalpituzumab tesirine (Rova-T)  
• TremelimumabNon-small cell lung cancer (NSCLC), stage IV, in combination with durvalumab, 1L 
• VeliparibBrain metastases from NSCLC 

Blaaskanker

• Atezolizumab Blaaskanker 
• DurvalumabLocally advanced or metastatic urothelial carcinoma (UC) whose disease has progressed during or after one standard platinum‑based regimen 
• Nivolumab  
• PembrolizumabTreatment (monotherapy) of locally advanced or metastatic urothelial carcinoma in adults who have received prior platinum-containing chemotherapy or who are not eligible for cisplatin chemotherapy 
• TremelimumabFirst line bladder cancer 

Leverkanker

• Nivolumab  
• Regorafenib  

Eierstokkanker

• Niraparib (tosylate monohydrate) 
• OlaparibTabletten ipv capsules voor onderhoudsbehandeling platinum sensitief recidief ovariumcarcinoom 
• Paclitaxel  
• Paclitaxel poliglumex 
• Rucaparib (camsylate)Ovarian cancer; BRCA-mutated or with BRCA-like mutation, platinum-sensitive, 2L of 3L 
• VeliparibSerous epithelial ovarian, fallopian tube or primary peritoneal cancer with BRCA1 mutation, stage II or IV high-grade - first-line with carboplatin and paclitaxel 

Multipel Myeloma

• Daratumumab 
• Denosumab 
• Pembrolizumab 
• Plitidepsin 

Neuro-endocriene kanker

• Telotristat etiprate 

Hoofd- en halskanker

• DurvalumabHead and neck (or upper airways tract) cancers; squamous cell carcinoma of head or neck (SCCHN), 2L monotherapy in PDL1-positive tumours or in combination with tremelimumab for PDL1-negative tumours. 
• PembrolizumabHead & Neck cancer 
• TremelimumabHead and neck cancer; squamous cell carcinoma of head or neck (SCCHN) 

Hoofd- en halkanker

• Nivolumab Advanced hepatocellular carcinoma (HCC) - first-line 

Lymfeklierkanker

• Blinatumomabadults with minimal residual disease (MRD) positive B-cell precursor acute lymphoblastic leukaemia (ALL) 
• Brentuximab vedotin 
• Brigatinib 
• CTL019Diffuse Large B-Cell Lymphoma (DLBCL): relapse and/or refractory patients, not eligible for SCT (3L?) 

• Ibrutinib

  • Ibrutinib
  • Ibrutinib
  • Ibrutinib
  • Ibrutinib
• Nivolumab  
• Obinutuzumab  

Multipel Myelom

• Lenalidomide 

Nierkanker

• AGS-003 
• Ipilimumab Renal cell carcinoma 

Borstvlieskanker

• Nintedanib 
• Nivolumab  

Alvleesklierkanker

• Masitinib

  • Masitinib
  • Masitinib
• Olaparib 
• Rucaparib (camsylate) 

Hersenkanker

• Brain cancer vaccine 
• Depatux-M 
• Veliparib 

Darmkanker

• Lutetium-177 
• MABp1 (interleukin 1 a human antibody) 
• MasitinibGIST 
• Nivolumab  

Prostaatkanker

• Abiraterone 
• OlaparibProstate cancer - monotherapy for BRCA 1/2 or ATM gene-mutated metastatic castration resistant prostate cancer (mCRPC) in patients who have received a prior taxane-based chemotherapy and at least one newer hormonal agent (abiraterone or enzalutamide) 
• Rilimogene galvacirepvec-rilimogene glafolivec 

Maagkanker

• PembrolizumabLocally advanced or metastatic gastric and gastroesophageal junction adenocarcinoma - second- and subsequent-line 

Hoofd-en halskanker

• Afatinib 

• NivolumabTreatment (monotherapy) of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) after prior chemotherapy. Patients with EGFR activating mutations or ALK-positive tumour mutations should also have received targeted therapy before receiving atezolizumab